Local Tech Wire

RALEIGH, N.C. – and recently announced an agreement for the development of a new oral insulin delivery system for type 1 diabetes.

The finalized arrangement provides for the development of a Siosome nanoparticle containing synthetic human insulin designed to be administered orally and then time-released into the bloodstream over a 12-hour period.

Financial terms and specific details have not been disclosed.

Under the agreement, Helia and Siogen will work together to develop this drug for canine type 1 diabetes. The project is currently underway with the goal leading the veterinary and medical world to a new personalized method to manage diabetes in a more controlled and patient-friendly manner.

Siogen Biotech is Malaysia-based company that focuses on developing nanoparticle delivery systems for many different drugs, compounds and substances. Helia Medical is a Wisconsin-based company with operations in Raleigh that uses many cutting-edge human medical developments and applies them to veterinary medical applications.

Many of the developments from this partnership should directly advance not only veterinary medicine, but also human medicine worldwide.

Get the latest news alerts: at Twitter.